ERBB2 and breast carcinoma: Targeted treatment with trastuzumab for HER2-positive breast cancer subtype was given to 43.7% and 62.9% (p = 0.054) of Barretos Cancer Hospital and InORP Oncoclinicas Group patients, respectively (Table 2).